Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KIVU-305 in Advanced Solid Tumors
NCT07545356Phase 1Recruiting
- Sponsor
- Kivu Bioscience
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of KIVU-305 in solid tumor (2 arms), sponsored by Kivu Bioscience. Primary endpoint: Maximum Tolerated Dose at 18 months. Started May 2026; status: recruiting.
02
Drugs
KIVU-305
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07545356.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07545356.